Australia Markets closed

Medtronic plc (MDT)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
118.26+2.99 (+2.59%)
At close: 4:00PM EST

116.66 -1.60 (-1.35%)
After hours: 6:20PM EST

Full screen
Trade prices are not sourced from all markets
Previous close115.27
Open115.71
Bid115.52 x 2200
Ask118.28 x 900
Day's range115.26 - 118.76
52-week range72.13 - 120.53
Volume4,488,600
Avg. volume4,459,193
Market cap159.352B
Beta (5Y monthly)0.74
PE ratio (TTM)52.35
EPS (TTM)2.26
Earnings date27 May 2021
Forward dividend & yield2.32 (1.97%)
Ex-dividend date21 Dec 2020
1y target est133.54
  • 4 Stocks to Watch as FDA Action Plan Stresses MedTech Digitization
    Zacks

    4 Stocks to Watch as FDA Action Plan Stresses MedTech Digitization

    These four MedTech stocks -- ABT, JNJ, MDT and MASI -- are expected to gain enormously from FDA's SaMD Action Plan 2021.

  • Medtronic Announces First Procedures in Pivotal Trial to Evaluate Novel Ablation Technology in Treating Atrial Fibrillation
    PR Newswire

    Medtronic Announces First Procedures in Pivotal Trial to Evaluate Novel Ablation Technology in Treating Atrial Fibrillation

    Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the first procedures in the investigational device exemption (IDE) pivotal trial to evaluate the PulseSelect™ Pulsed Field Ablation (PFA) System, a novel, breakthrough technology that uses pulsed electric fields to treat atrial fibrillation (AF). The first procedure in the PULSED AF pivotal trial was performed this week at Southcoast Health by Nitesh Sood, M.D., Fall River, Massachusetts; the second procedure was performed by Arnoldas Giedrimas, M.D., also at Southcoast Health. The PULSED AF Trial is the first global, pre-market, multi-center clinical study with IDE approval aimed to establish the safety and efficacy of the PulseSelect System.

  • Medtronic's (MDT) REVERSE Trial Indicates CRT's Benefits for HF
    Zacks

    Medtronic's (MDT) REVERSE Trial Indicates CRT's Benefits for HF

    Medtronic's (MDT) REVERSE analysis highlights the role played by CRT to slow the progression of HF, thus reinforcing the strong clinical evidence supporting CRT.